Loading…

Barriers and facilitators to viral hepatitis testing in Uzbekistan: scoping qualitative study among key stakeholders, healthcare workers, and the general population

In the World Health Organization European Region, an estimated 14 million people live with a chronic hepatitis B virus infection (HBV), and 12 million are affected by a hepatitis C virus infection (HCV). Uzbekistan bears a major burden of HBV and has one of the highest HCV prevalence in the region....

Full description

Saved in:
Bibliographic Details
Published in:BMC public health 2024-06, Vol.24 (1), p.1482-1482, Article 1482
Main Authors: Mazhnaya, Alyona, Geurts, Brogan, Brigida, Krestina, Bakieva, Shokhista, Sadirova, Shakhlo, Witzigmann, Annika, Musabaev, Erkin, Brandl, Michael, Weishaar, Heide, Dudareva, Sandra, Bcheraoui, Charbel El
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c445t-70010c6d21ab326fc502070d7297a6d28b16d47b938c69b7b2ffbfd566a75da63
container_end_page 1482
container_issue 1
container_start_page 1482
container_title BMC public health
container_volume 24
creator Mazhnaya, Alyona
Geurts, Brogan
Brigida, Krestina
Bakieva, Shokhista
Sadirova, Shakhlo
Witzigmann, Annika
Musabaev, Erkin
Brandl, Michael
Weishaar, Heide
Dudareva, Sandra
Bcheraoui, Charbel El
description In the World Health Organization European Region, an estimated 14 million people live with a chronic hepatitis B virus infection (HBV), and 12 million are affected by a hepatitis C virus infection (HCV). Uzbekistan bears a major burden of HBV and has one of the highest HCV prevalence in the region. Following a presidential decree in May 2022, significant funds were allocated to the viral hepatitis (VH) elimination program in Uzbekistan. The program expands VH testing to reach 500,000 people annually during 2022-2025 as part of the VH elimination strategy that includes the provision of free testing and affordable treatment. Exploring the existing barriers and facilitators to VH testing is pivotal for informing these interventions. This study uses a cross-sectional qualitative design to identify and explore the barriers and facilitators to VH testing among the general population in Uzbekistan. We collected data during October-November 2022 through semi-structured interviews with 12 key informants (KIs) and 7 focus group discussions with two target populations: the general population and healthcare workers (HCW) in Tashkent, Uzbekistan. Following the capability-opportunity-motivation-behavior model (COM-B model) as a framework for the analysis, we identified major capability barriers to VH testing primarily linked to low health literacy and limited knowledge about VH types, symptoms, transmission, testing and treatment. Physical opportunity barriers included the time and financial costs associated with testing, diagnostics, and treatment. Sociocultural opportunity barriers involved anticipated negative reactions and stigmatization, particularly affecting women. Motivational barriers included a reluctance to be tested when asymptomatic and a general fear of receiving positive test results. The involvement of healthcare workers in promoting VH awareness and motivating the general population emerged as a facilitator. A multi-pronged approach is recommended to achieve VH testing goals among the general population, focusing on raising awareness and health literacy and creating an enabling environment that ensures easy accessibility and minimizing VH testing-associated costs.
doi_str_mv 10.1186/s12889-024-18953-5
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_fcf877044aca4049891bb5ff7a26f89b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A796233744</galeid><doaj_id>oai_doaj_org_article_fcf877044aca4049891bb5ff7a26f89b</doaj_id><sourcerecordid>A796233744</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-70010c6d21ab326fc502070d7297a6d28b16d47b938c69b7b2ffbfd566a75da63</originalsourceid><addsrcrecordid>eNptks9u1DAQxiMEoqXwAhxQJC4cSLEdJ3a4oFLxp1IlLvRsTRx717vZOLWdRcvz8KBMdkvpIpRDki_z_SYz_rLsJSXnlMr6XaRMyqYgjBdUNlVZVI-yU8oFLRiv5OMHzyfZsxhXhFAhK_Y0OymlLNFcnWa_PkIIzoSYw9DlFrTrXYLkUUg-37oAfb40IySXHEomJjcscjfkNz9bs3YxwfA-j9qPs3w7wd7ttiaPaep2OWw86muzw3dYm6XvO-z1FpHQp6WGYPIfPqz32vwDaWnyhRnM3Hb049QjzA_PsycW-mhe3N3PspvPn75ffi2uv325ury4LjTnVSoEDkh03TEKbclqqyvCiCCdYI0AlGVL646LtimlrptWtMza1nZVXYOoOqjLs-zqwO08rNQY3AbCTnlwai_4sFAQktO9UVZbKQThHDRwwhvZ0LatrBWAjWXTIuvDgTVO7cZ02gwJhzqCHn8Z3FIt_FZRSvHESoaEN3eE4G8n3LzauKhN38Ng_BRVSWpeiaYhHEtf_1O68lMYcFdzVS3x1IX4W7UAnMAN1mNjPUPVhWhqVpaCz6zz_1Th1ZmN034w1qF-ZGAHgw4-xmDs_ZCUqDmo6hBUhUFV-6CqCk2vHq7n3vInmeVvJOPmuA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3066885277</pqid></control><display><type>article</type><title>Barriers and facilitators to viral hepatitis testing in Uzbekistan: scoping qualitative study among key stakeholders, healthcare workers, and the general population</title><source>PMC (PubMed Central)</source><source>Publicly Available Content (ProQuest)</source><source>Coronavirus Research Database</source><creator>Mazhnaya, Alyona ; Geurts, Brogan ; Brigida, Krestina ; Bakieva, Shokhista ; Sadirova, Shakhlo ; Witzigmann, Annika ; Musabaev, Erkin ; Brandl, Michael ; Weishaar, Heide ; Dudareva, Sandra ; Bcheraoui, Charbel El</creator><creatorcontrib>Mazhnaya, Alyona ; Geurts, Brogan ; Brigida, Krestina ; Bakieva, Shokhista ; Sadirova, Shakhlo ; Witzigmann, Annika ; Musabaev, Erkin ; Brandl, Michael ; Weishaar, Heide ; Dudareva, Sandra ; Bcheraoui, Charbel El</creatorcontrib><description>In the World Health Organization European Region, an estimated 14 million people live with a chronic hepatitis B virus infection (HBV), and 12 million are affected by a hepatitis C virus infection (HCV). Uzbekistan bears a major burden of HBV and has one of the highest HCV prevalence in the region. Following a presidential decree in May 2022, significant funds were allocated to the viral hepatitis (VH) elimination program in Uzbekistan. The program expands VH testing to reach 500,000 people annually during 2022-2025 as part of the VH elimination strategy that includes the provision of free testing and affordable treatment. Exploring the existing barriers and facilitators to VH testing is pivotal for informing these interventions. This study uses a cross-sectional qualitative design to identify and explore the barriers and facilitators to VH testing among the general population in Uzbekistan. We collected data during October-November 2022 through semi-structured interviews with 12 key informants (KIs) and 7 focus group discussions with two target populations: the general population and healthcare workers (HCW) in Tashkent, Uzbekistan. Following the capability-opportunity-motivation-behavior model (COM-B model) as a framework for the analysis, we identified major capability barriers to VH testing primarily linked to low health literacy and limited knowledge about VH types, symptoms, transmission, testing and treatment. Physical opportunity barriers included the time and financial costs associated with testing, diagnostics, and treatment. Sociocultural opportunity barriers involved anticipated negative reactions and stigmatization, particularly affecting women. Motivational barriers included a reluctance to be tested when asymptomatic and a general fear of receiving positive test results. The involvement of healthcare workers in promoting VH awareness and motivating the general population emerged as a facilitator. A multi-pronged approach is recommended to achieve VH testing goals among the general population, focusing on raising awareness and health literacy and creating an enabling environment that ensures easy accessibility and minimizing VH testing-associated costs.</description><identifier>ISSN: 1471-2458</identifier><identifier>EISSN: 1471-2458</identifier><identifier>DOI: 10.1186/s12889-024-18953-5</identifier><identifier>PMID: 38831285</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; Barriers and facilitators ; Behavior change ; Care and treatment ; Central Asia ; Chronic illnesses ; Chronic infection ; Cross-Sectional Studies ; Diagnosis ; Disease transmission ; Elimination ; Female ; Females ; Focus Groups ; Health behavior ; Health care ; Health Personnel - psychology ; Health Services Accessibility ; Hepatitis ; Hepatitis B ; Hepatitis C ; Hepatitis testing ; Hepatitis, Viral ; Hepatitis, Viral, Human - diagnosis ; Hepatitis, Viral, Human - epidemiology ; Hepatitis, Viral, Human - prevention &amp; control ; Humans ; Immunization ; Infections ; Interviews as Topic ; Literacy ; Male ; Mass Screening ; Medical personnel ; Middle Aged ; Pilot projects ; Population ; Practice ; Prevention ; Primary care ; Public health ; Qualitative Research ; Risk factors ; Stakeholder Participation ; Uzbekistan</subject><ispartof>BMC public health, 2024-06, Vol.24 (1), p.1482-1482, Article 1482</ispartof><rights>2024. The Author(s).</rights><rights>COPYRIGHT 2024 BioMed Central Ltd.</rights><rights>2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c445t-70010c6d21ab326fc502070d7297a6d28b16d47b938c69b7b2ffbfd566a75da63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11145832/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3066885277?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25732,27903,27904,36991,36992,38495,43874,44569,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38831285$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mazhnaya, Alyona</creatorcontrib><creatorcontrib>Geurts, Brogan</creatorcontrib><creatorcontrib>Brigida, Krestina</creatorcontrib><creatorcontrib>Bakieva, Shokhista</creatorcontrib><creatorcontrib>Sadirova, Shakhlo</creatorcontrib><creatorcontrib>Witzigmann, Annika</creatorcontrib><creatorcontrib>Musabaev, Erkin</creatorcontrib><creatorcontrib>Brandl, Michael</creatorcontrib><creatorcontrib>Weishaar, Heide</creatorcontrib><creatorcontrib>Dudareva, Sandra</creatorcontrib><creatorcontrib>Bcheraoui, Charbel El</creatorcontrib><title>Barriers and facilitators to viral hepatitis testing in Uzbekistan: scoping qualitative study among key stakeholders, healthcare workers, and the general population</title><title>BMC public health</title><addtitle>BMC Public Health</addtitle><description>In the World Health Organization European Region, an estimated 14 million people live with a chronic hepatitis B virus infection (HBV), and 12 million are affected by a hepatitis C virus infection (HCV). Uzbekistan bears a major burden of HBV and has one of the highest HCV prevalence in the region. Following a presidential decree in May 2022, significant funds were allocated to the viral hepatitis (VH) elimination program in Uzbekistan. The program expands VH testing to reach 500,000 people annually during 2022-2025 as part of the VH elimination strategy that includes the provision of free testing and affordable treatment. Exploring the existing barriers and facilitators to VH testing is pivotal for informing these interventions. This study uses a cross-sectional qualitative design to identify and explore the barriers and facilitators to VH testing among the general population in Uzbekistan. We collected data during October-November 2022 through semi-structured interviews with 12 key informants (KIs) and 7 focus group discussions with two target populations: the general population and healthcare workers (HCW) in Tashkent, Uzbekistan. Following the capability-opportunity-motivation-behavior model (COM-B model) as a framework for the analysis, we identified major capability barriers to VH testing primarily linked to low health literacy and limited knowledge about VH types, symptoms, transmission, testing and treatment. Physical opportunity barriers included the time and financial costs associated with testing, diagnostics, and treatment. Sociocultural opportunity barriers involved anticipated negative reactions and stigmatization, particularly affecting women. Motivational barriers included a reluctance to be tested when asymptomatic and a general fear of receiving positive test results. The involvement of healthcare workers in promoting VH awareness and motivating the general population emerged as a facilitator. A multi-pronged approach is recommended to achieve VH testing goals among the general population, focusing on raising awareness and health literacy and creating an enabling environment that ensures easy accessibility and minimizing VH testing-associated costs.</description><subject>Adult</subject><subject>Barriers and facilitators</subject><subject>Behavior change</subject><subject>Care and treatment</subject><subject>Central Asia</subject><subject>Chronic illnesses</subject><subject>Chronic infection</subject><subject>Cross-Sectional Studies</subject><subject>Diagnosis</subject><subject>Disease transmission</subject><subject>Elimination</subject><subject>Female</subject><subject>Females</subject><subject>Focus Groups</subject><subject>Health behavior</subject><subject>Health care</subject><subject>Health Personnel - psychology</subject><subject>Health Services Accessibility</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis C</subject><subject>Hepatitis testing</subject><subject>Hepatitis, Viral</subject><subject>Hepatitis, Viral, Human - diagnosis</subject><subject>Hepatitis, Viral, Human - epidemiology</subject><subject>Hepatitis, Viral, Human - prevention &amp; control</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infections</subject><subject>Interviews as Topic</subject><subject>Literacy</subject><subject>Male</subject><subject>Mass Screening</subject><subject>Medical personnel</subject><subject>Middle Aged</subject><subject>Pilot projects</subject><subject>Population</subject><subject>Practice</subject><subject>Prevention</subject><subject>Primary care</subject><subject>Public health</subject><subject>Qualitative Research</subject><subject>Risk factors</subject><subject>Stakeholder Participation</subject><subject>Uzbekistan</subject><issn>1471-2458</issn><issn>1471-2458</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptks9u1DAQxiMEoqXwAhxQJC4cSLEdJ3a4oFLxp1IlLvRsTRx717vZOLWdRcvz8KBMdkvpIpRDki_z_SYz_rLsJSXnlMr6XaRMyqYgjBdUNlVZVI-yU8oFLRiv5OMHzyfZsxhXhFAhK_Y0OymlLNFcnWa_PkIIzoSYw9DlFrTrXYLkUUg-37oAfb40IySXHEomJjcscjfkNz9bs3YxwfA-j9qPs3w7wd7ttiaPaep2OWw86muzw3dYm6XvO-z1FpHQp6WGYPIfPqz32vwDaWnyhRnM3Hb049QjzA_PsycW-mhe3N3PspvPn75ffi2uv325ury4LjTnVSoEDkh03TEKbclqqyvCiCCdYI0AlGVL646LtimlrptWtMza1nZVXYOoOqjLs-zqwO08rNQY3AbCTnlwai_4sFAQktO9UVZbKQThHDRwwhvZ0LatrBWAjWXTIuvDgTVO7cZ02gwJhzqCHn8Z3FIt_FZRSvHESoaEN3eE4G8n3LzauKhN38Ng_BRVSWpeiaYhHEtf_1O68lMYcFdzVS3x1IX4W7UAnMAN1mNjPUPVhWhqVpaCz6zz_1Th1ZmN034w1qF-ZGAHgw4-xmDs_ZCUqDmo6hBUhUFV-6CqCk2vHq7n3vInmeVvJOPmuA</recordid><startdate>20240603</startdate><enddate>20240603</enddate><creator>Mazhnaya, Alyona</creator><creator>Geurts, Brogan</creator><creator>Brigida, Krestina</creator><creator>Bakieva, Shokhista</creator><creator>Sadirova, Shakhlo</creator><creator>Witzigmann, Annika</creator><creator>Musabaev, Erkin</creator><creator>Brandl, Michael</creator><creator>Weishaar, Heide</creator><creator>Dudareva, Sandra</creator><creator>Bcheraoui, Charbel El</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L6V</scope><scope>M0S</scope><scope>M1P</scope><scope>M7S</scope><scope>PATMY</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240603</creationdate><title>Barriers and facilitators to viral hepatitis testing in Uzbekistan: scoping qualitative study among key stakeholders, healthcare workers, and the general population</title><author>Mazhnaya, Alyona ; Geurts, Brogan ; Brigida, Krestina ; Bakieva, Shokhista ; Sadirova, Shakhlo ; Witzigmann, Annika ; Musabaev, Erkin ; Brandl, Michael ; Weishaar, Heide ; Dudareva, Sandra ; Bcheraoui, Charbel El</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-70010c6d21ab326fc502070d7297a6d28b16d47b938c69b7b2ffbfd566a75da63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Barriers and facilitators</topic><topic>Behavior change</topic><topic>Care and treatment</topic><topic>Central Asia</topic><topic>Chronic illnesses</topic><topic>Chronic infection</topic><topic>Cross-Sectional Studies</topic><topic>Diagnosis</topic><topic>Disease transmission</topic><topic>Elimination</topic><topic>Female</topic><topic>Females</topic><topic>Focus Groups</topic><topic>Health behavior</topic><topic>Health care</topic><topic>Health Personnel - psychology</topic><topic>Health Services Accessibility</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis C</topic><topic>Hepatitis testing</topic><topic>Hepatitis, Viral</topic><topic>Hepatitis, Viral, Human - diagnosis</topic><topic>Hepatitis, Viral, Human - epidemiology</topic><topic>Hepatitis, Viral, Human - prevention &amp; control</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infections</topic><topic>Interviews as Topic</topic><topic>Literacy</topic><topic>Male</topic><topic>Mass Screening</topic><topic>Medical personnel</topic><topic>Middle Aged</topic><topic>Pilot projects</topic><topic>Population</topic><topic>Practice</topic><topic>Prevention</topic><topic>Primary care</topic><topic>Public health</topic><topic>Qualitative Research</topic><topic>Risk factors</topic><topic>Stakeholder Participation</topic><topic>Uzbekistan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mazhnaya, Alyona</creatorcontrib><creatorcontrib>Geurts, Brogan</creatorcontrib><creatorcontrib>Brigida, Krestina</creatorcontrib><creatorcontrib>Bakieva, Shokhista</creatorcontrib><creatorcontrib>Sadirova, Shakhlo</creatorcontrib><creatorcontrib>Witzigmann, Annika</creatorcontrib><creatorcontrib>Musabaev, Erkin</creatorcontrib><creatorcontrib>Brandl, Michael</creatorcontrib><creatorcontrib>Weishaar, Heide</creatorcontrib><creatorcontrib>Dudareva, Sandra</creatorcontrib><creatorcontrib>Bcheraoui, Charbel El</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Engineering Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Engineering Database</collection><collection>Environmental Science Database</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>BMC public health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mazhnaya, Alyona</au><au>Geurts, Brogan</au><au>Brigida, Krestina</au><au>Bakieva, Shokhista</au><au>Sadirova, Shakhlo</au><au>Witzigmann, Annika</au><au>Musabaev, Erkin</au><au>Brandl, Michael</au><au>Weishaar, Heide</au><au>Dudareva, Sandra</au><au>Bcheraoui, Charbel El</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Barriers and facilitators to viral hepatitis testing in Uzbekistan: scoping qualitative study among key stakeholders, healthcare workers, and the general population</atitle><jtitle>BMC public health</jtitle><addtitle>BMC Public Health</addtitle><date>2024-06-03</date><risdate>2024</risdate><volume>24</volume><issue>1</issue><spage>1482</spage><epage>1482</epage><pages>1482-1482</pages><artnum>1482</artnum><issn>1471-2458</issn><eissn>1471-2458</eissn><abstract>In the World Health Organization European Region, an estimated 14 million people live with a chronic hepatitis B virus infection (HBV), and 12 million are affected by a hepatitis C virus infection (HCV). Uzbekistan bears a major burden of HBV and has one of the highest HCV prevalence in the region. Following a presidential decree in May 2022, significant funds were allocated to the viral hepatitis (VH) elimination program in Uzbekistan. The program expands VH testing to reach 500,000 people annually during 2022-2025 as part of the VH elimination strategy that includes the provision of free testing and affordable treatment. Exploring the existing barriers and facilitators to VH testing is pivotal for informing these interventions. This study uses a cross-sectional qualitative design to identify and explore the barriers and facilitators to VH testing among the general population in Uzbekistan. We collected data during October-November 2022 through semi-structured interviews with 12 key informants (KIs) and 7 focus group discussions with two target populations: the general population and healthcare workers (HCW) in Tashkent, Uzbekistan. Following the capability-opportunity-motivation-behavior model (COM-B model) as a framework for the analysis, we identified major capability barriers to VH testing primarily linked to low health literacy and limited knowledge about VH types, symptoms, transmission, testing and treatment. Physical opportunity barriers included the time and financial costs associated with testing, diagnostics, and treatment. Sociocultural opportunity barriers involved anticipated negative reactions and stigmatization, particularly affecting women. Motivational barriers included a reluctance to be tested when asymptomatic and a general fear of receiving positive test results. The involvement of healthcare workers in promoting VH awareness and motivating the general population emerged as a facilitator. A multi-pronged approach is recommended to achieve VH testing goals among the general population, focusing on raising awareness and health literacy and creating an enabling environment that ensures easy accessibility and minimizing VH testing-associated costs.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>38831285</pmid><doi>10.1186/s12889-024-18953-5</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1471-2458
ispartof BMC public health, 2024-06, Vol.24 (1), p.1482-1482, Article 1482
issn 1471-2458
1471-2458
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_fcf877044aca4049891bb5ff7a26f89b
source PMC (PubMed Central); Publicly Available Content (ProQuest); Coronavirus Research Database
subjects Adult
Barriers and facilitators
Behavior change
Care and treatment
Central Asia
Chronic illnesses
Chronic infection
Cross-Sectional Studies
Diagnosis
Disease transmission
Elimination
Female
Females
Focus Groups
Health behavior
Health care
Health Personnel - psychology
Health Services Accessibility
Hepatitis
Hepatitis B
Hepatitis C
Hepatitis testing
Hepatitis, Viral
Hepatitis, Viral, Human - diagnosis
Hepatitis, Viral, Human - epidemiology
Hepatitis, Viral, Human - prevention & control
Humans
Immunization
Infections
Interviews as Topic
Literacy
Male
Mass Screening
Medical personnel
Middle Aged
Pilot projects
Population
Practice
Prevention
Primary care
Public health
Qualitative Research
Risk factors
Stakeholder Participation
Uzbekistan
title Barriers and facilitators to viral hepatitis testing in Uzbekistan: scoping qualitative study among key stakeholders, healthcare workers, and the general population
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T03%3A03%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Barriers%20and%20facilitators%20to%20viral%20hepatitis%20testing%20in%20Uzbekistan:%20scoping%20qualitative%20study%20among%20key%20stakeholders,%20healthcare%20workers,%20and%20the%20general%20population&rft.jtitle=BMC%20public%20health&rft.au=Mazhnaya,%20Alyona&rft.date=2024-06-03&rft.volume=24&rft.issue=1&rft.spage=1482&rft.epage=1482&rft.pages=1482-1482&rft.artnum=1482&rft.issn=1471-2458&rft.eissn=1471-2458&rft_id=info:doi/10.1186/s12889-024-18953-5&rft_dat=%3Cgale_doaj_%3EA796233744%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c445t-70010c6d21ab326fc502070d7297a6d28b16d47b938c69b7b2ffbfd566a75da63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3066885277&rft_id=info:pmid/38831285&rft_galeid=A796233744&rfr_iscdi=true